ID   HCC1569 GDC-0941_resistant
AC   CVCL_A1FP
DR   cancercelllines; CVCL_A1FP
DR   Wikidata; Q102114105
RX   PubMed=26759240;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; GDC-0941).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1100Thr (c.3299A>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1862fs*1 (c.5578delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3701; FHIT; Simple; p.Val97Phe (c.289G>T) (651G>T); dbSNP=rs139666727; Zygosity=Heterozygous; Note=Germline (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4017; Breast ductal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1255 ! HCC1569
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//